Thursday plan: keep the growth book unchanged while testing the AI rebound
Thursday's morning plan carries the live portfolio forward without a resize. Wednesday's gains supported the existing growth exposure, led by NVDA and MRNA, but weak 20-day technology momentum, rate sensitivity, and META's legal risk keep the stance cautious.
Published Oct 22, 2026Open Market Journal4 min readAI-assisted research · methodologyNot investment advice
- Opened MRNA at 16%
- Trimmed META from 30% to 14%
Grade: A. The prior plan to hold the cautious growth book worked on Wednesday, with the portfolio gaining 1.02% against SPY's 0.53%.
Since Last Session
Wednesday finished with every holding except AMZN higher. NVDA led with a 2.54% gain, followed by MRNA at 1.54%. META rose 0.47%, MSFT added 0.2%, and AMZN slipped 0.1%. The weighted book gained 1.02% versus 0.53% for SPY.
Regime Check
Regime: R3. Company-level growth leadership remains investable, but broad technology momentum is still weak enough to demand selectivity.
Supporting: QQQ gained 1.05% Wednesday and held slightly positive 0.28% 60-day momentum. NVDA's 2.54% gain supported stabilization near its 60-day average. MSFT remains above both moving averages, MRNA retains strong 20-day and 60-day momentum, and META's reported monetization roadmap followed a strong quarter and guide. VIX at 16.68 and the portfolio's normal drawdown protocol stage don't signal acute stress.
Contradicting: QQQ remains down 1.88% over 20 days and below its 20-day average. XLK has negative 3.06% 20-day momentum, while NVDA and META also retain negative 20-day momentum. CoreWeave's reported bond-yield pressure shows that financing conditions can still punish the weaker edges of AI infrastructure. META's reported $25 billion penalty adds a separate company-specific risk.
Plan for Thursday
Carry the existing holdings and weights into Thursday unchanged. This morning publication isn't the allocation cycle, so any new decision belongs in the separate pre-close review.
The open should confirm whether Wednesday's growth participation can persist beyond a single rebound. NVDA needs continued demand without a rapid reversal, MSFT should retain its relative stability, and META must absorb the legal headline without renewed deterioration. MRNA can remain a useful independent growth engine if its leadership survives broader healthcare weakness. AMZN doesn't need immediate acceleration, but continued lagging alongside stronger technology would reduce its relative appeal at the later decision point.
Positioning
2 of 5 lines changed · weights sum to 100% · published Oct 22, 2026- META14%was 30%
Positive 60-day momentum and the monetization roadmap support the thesis; negative 20-day momentum and the reported penalty oppose it.
- MRNA16%was 0%
A 1.54% Wednesday gain extended strong 20-day and 60-day momentum.
- MSFT29%unchanged
Positive 20-day and 60-day momentum, price above both moving averages, and a 0.2% Wednesday gain.
- AMZN15%unchanged
Positive 20-day and 60-day momentum remain in place, though Wednesday produced a 0.1% decline.
- NVDA26%unchanged
Wednesday's 2.54% gain improved stabilization evidence, but 20-day momentum remains negative.
Wed+2.54%
The book remains fully invested. MSFT and NVDA account for 55% between them, so Thursday's result will remain heavily tied to durable AI spending and execution by the two largest positions. The drawdown stands at 3.69% from peak, with the protocol still at normal.
Institutional Signals
Institutional filings support conviction in durable growth franchises, but they remain slow-moving context. Pershing Square's 2026-05-15 filing showed AMZN at 17.4% and MSFT at 15.3%, which aligns with the book's emphasis on cloud and software economics. Bridgewater's 2026-08-14 filing included NVDA at 3.2% alongside large broad-market ETF positions, signaling participation in AI leadership within a wider portfolio. Scion's NVDA position comes from a 2025-11-03 filing and is too stale to treat as a current trading signal.
What Could Break It
- A hyperscaler capital-spending cut or deferral would challenge NVDA and weaken the broader AI demand chain.
- Rising infrastructure spending without faster cloud or AI monetization would damage the MSFT and AMZN earnings case.
- META's legal and privacy costs could overwhelm improving monetization if they begin to impair operating economics.
- A sharp MRNA momentum reversal accompanied by weaker clinical or commercial evidence would invalidate the new position's growth thesis.
- Continued negative technology momentum with failed follow-through from Wednesday would show that leadership remains too narrow to support the book's concentration.
Sources and evidence
- Meta put out an ambitious roadmap to Muse monetization after strong quarter and guide · CNBC
- Inside India newsletter: Asia’s hottest data center market aims to quell concerns over water and power use · CNBC
- Tesla beats on earnings and sales even as auto revenue declines · CNBC
- Tesla beats earnings projections after Musk floats SpaceX merger plan · The Guardian
- CoreWeave’s market confidence erodes as bond yields spike and stock sinks · CNBC
- IBM beats on top and bottom lines as CEO Krishna touts 'Super Intelligence' traction · CNBC
- Southwest Airlines cuts 2026 profit forecast on higher fuel · CNBC
- Trump-aligned super PACs pour millions into once-safe GOP House seats · CNBC
- GM aims to develop vehicles in as little as two years with AI, software push · CNBC
- Meta ordered to pay $25 billion penalty in New Mexico Cambridge Analytica case · CNBC
- Musk's SpaceX stock gift is 'tip of the iceberg' for Trump Accounts, Altimeter's Gerstner says · CNBC
- Apple's iPhone Duo in short supply — plus, the 2 stocks fueling an AI rebound · CNBC